Archived Press Releases
March 24, 1999
DTI LINK Grant - New Generation Cancer Vaccines
March 24, 1999. Onyvax Limited (London, UK;http://www.onyvax.com)
has received a grant of up to £313,000 awarded under the Cell
Engineering LINK Programme by the Department of Trade & Industry.
The DTI grant will help to support a three year collaborative programme
at St George's Hospital Medical School under the direction of Angus
Dalgleish, Professor of Clinical Oncology, for the development of
second generation cancer vaccines.
Onyvax is a private company focussed on the development of therapies
that harness the power of the immune system in the fight against
cancer. It is believed that such an approach will benefit from the
power and selectivity of the immune system whilst offering an excellent
side-ef fect profile. To this end, Onyvax is developing vaccines
targeted to specific cancers. The first, for prostate cancer, is
currently being evaluated at St. George's Hospital in a phase I/II
clinical study being conducted by the Urology Research Group.
Under the new collaborative research programme supported by the
DTI, Onyvax and SGHMS will conduct research into generation prostate
cancer vaccines, broadening and deepening the scope of the research
programmes already in place in both parties' laboratories. Onyvax
has negotiated an exclusive licence to all of the intellectual property
generated by the project.
Anthony Walker, Chief Executive said: "We are delighted with
the award of the LINK grant and the recognition by the DTI of the
promise of our vaccine technology. The team at SGHMS is amongst
the foremost engaged in the field of tumour immunology and the added
resources being brought to bear will accelerate the development
of safe and effective new treatments for cancer."